- $87.18m
- $75.85m
- $27.07m
Annual income statement for Tecogen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 24.4 | 25 | 25.1 | 22.6 | 27.1 |
| Cost of Revenue | |||||
| Gross Profit | 11.6 | 11.1 | 10.2 | 9.87 | 9.82 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 20.6 | 27.4 | 29.6 | 27.2 | 35.3 |
| Operating Profit | 3.83 | -2.35 | -4.41 | -4.53 | -8.24 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 3.76 | -2.38 | -4.49 | -4.65 | -8.23 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 3.74 | -2.4 | -4.52 | -4.67 | -8.25 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 3.7 | -2.45 | -4.6 | -4.76 | -8.25 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 3.7 | -2.45 | -4.6 | -4.76 | -8.25 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.017 | -0.099 | -0.186 | -0.186 | -0.276 |